Myrobalan News
![](https://myrotx.com/wp-content/uploads/2024/10/Robin-Kleiman56-scaled.webp)
Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer
![](https://myrotx.com/wp-content/uploads/2024/10/photo_Emma-Reeve.webp)
Myrobalan Therapeutics Strengthens Board of Directors with Appointment of Emma Reeve
![](https://myrotx.com/wp-content/uploads/2024/09/ectrims_logo.webp)
Myrobalan Presents GPR17 Antagonist Preclinical Data at ECTRIMS 2024
![](https://myrotx.com/wp-content/uploads/2024/08/news_photo_bogleGrant.webp)
Myrobalan Therapeutics Names Grant Bogle to Board of Directors
![](https://myrotx.com/wp-content/uploads/2024/05/Guoping_Feng_1920x1080_c8a2f5a102-e1724259081263.webp)
Co-Founder, Professor Guoping Feng (MIT/Broad) Inducted into the National Academy of Sciences
![](https://myrotx.com/wp-content/uploads/2024/02/R8UXUPW_200x200.webp)
Myrobalan Therapeutics Receives a Grant from the ALS Association to Advance its CSF1R Inhibitor Program
Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential
![](https://myrotx.com/wp-content/uploads/2023/10/national_academy_of_medicine_logo.webp)
Co-Founder, Professor Guoping Feng (MIT/Broad) Inducted into the National Academy of Medicines
![](https://myrotx.com/wp-content/uploads/2023/10/PXL_20230429_171353060_a6b46a076e.webp)